Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning

Jul 16 2010

• By The Pink Sheet Daily

Related Content

Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing

Nov 22 2004

Grassley Stumbles In Comments On Meridia’s Regulatory History

Nov 18 2005

First-Time Generics Of Sanofi-Aventis’ Arava Enter Market

Sep 14 2005

Advisory Committee Rejects Avandia Vs. Actos Comparison Data

Aug 06 2007

Avandia's TIDE May Come In Smaller

Jul 14 2010

Grassley And Baucus Turn Up Heat On GSK With Attack On Avandia Data Handling

Jul 13 2010

Avandia Safety Rhetoric Ramps Up Ahead Of Advisory Committee Review

Jul 05 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window